Can CBD Change the Structure of a Brain? What the Plasticity Research Says

There is a particular kind of claim that should make any reasonable person suspicious. It usually arrives as a sentence like "CBD rebuilds the brain", and it is shared by people with genuine curiosity and people selling things, which is precisely why it deserves a careful look rather than a dismissal.

The underlying idea is not crazy. Brains are physically changeable structures. They rewire themselves in response to learning, injury and exercise, and the cells that do the wiring, called neurons, grow new connections called synapses. The process is called plasticity. It is real, it is measurable, and it is one of the most actively studied areas in neuroscience.

What has been less clear is whether cannabinoids have any meaningful effect on it. A decade of research has produced a body of work that is genuinely interesting and that most public writing has flattened into something much more confident than it deserves.

This is an attempt to say what the evidence actually shows, in a world where "neuroplasticity" has become a marketing word.

What brain plasticity is, precisely

Plasticity comes in several flavours, and the distinction matters because researchers do not mean the same thing by it.

Synaptic plasticity is the most studied form. It is the strengthening and weakening of existing connections between neurons. Every time you learn something, particular synapses get stronger and others get weaker. The molecular version of this involves receptors, and that is where cannabinoids come in, because the endocannabinoid system is one of the main systems that modulates synaptic transmission.

Structural plasticity is the physical growth and retraction of neuronal connections. New dendrites grow, existing ones thicken, spines form and are pruned. This is what "changing the structure of a brain" actually refers to, and it is much slower and harder to measure than synaptic plasticity.

Neurogenesis is the most dramatic and the most contested. It is the birth of new neurons. In adult humans, this happens primarily in the hippocampus, and the question of how much and under what conditions has been argued over for decades. The traditional view was that you make very few new neurons as an adult. That view has been substantially revised, though the extent of adult neurogenesis in humans is still genuinely unsettled.

Functional plasticity is the brain recruiting different regions for a task. It is the reason a taxi driver has a differently-shaped hippocampus than a bus driver, and it is the most immediately relevant to how people talk about "rewiring".

The important thing to hold onto is that these are different biological claims with different evidence standards, and much of the confusion in public writing comes from sliding between them.

Why the endocannabinoid system is a plasticity system

Here is the mechanism that makes the question reasonable in the first place.

The endocannabinoid system is a widespread signalling system. It has two main receptors, CB1 and CB2, and its job appears to be a form of negative feedback. When neurotransmitter release gets too high, the postsynaptic cell releases endocannabinoids retrogradely, travelling backwards across the synapse to tell the presynaptic cell to reduce its own output.

This is a brake, not an accelerator. It is how neurons avoid being over-stimulated, which matters because sustained over-stimulation is how neurons get damaged.

Cannabinoids like CBD interact with this system. CBD has a low affinity for CB1 and CB2, which is often misread as "it does nothing". It does not. Its main action at CB1 is as a negative allosteric modulator, meaning where it does bind, it reduces how strongly the receptor responds to other cannabinoids.

So the honest opening is this. The endocannabinoid system is a central regulator of synaptic function, and interfering with it is therefore a plausible way to affect plasticity. Plausible is the right word, and it is a considerably smaller claim than "CBD rebuilds the brain".

What the animal studies found

This is where the evidence is thickest, and where the interpretation is most contested.

A 2025 paper in Veterinary World reported that cannabidiol reversed depression-like behaviours in rats by enhancing hippocampal synaptic plasticity. The finding is that CBD produced measurable change in plasticity markers in the hippocampus alongside behavioural change, and the proposed mechanism runs through the CB1 receptor.

A 2025 paper in International Journal of Molecular Sciences looked at CBD lipid nanoparticles and their effect on gut-brain-bone axis integrity, with an explicit neuroplasticity endpoint. The formulation angle is notable. Working with plain CBD gives poor brain exposure, and the nanoparticle work is partly about solving that so effects are large enough to study at all.

A 2026 paper in Neuropharmacology found that cannabidiol attenuated seizure progression and the recognition memory deficit induced by a hippocampal channel mechanism. Reading this one carefully is instructive. It is a seizure model, and a fairly severe one, so the effect size is not a guide to anything in healthy people.

A 2026 paper in Frontiers in Neuroscience separated two processes that are often conflated, looking at how CBD differentially affected inhibitory avoidance memory reconsolidation and consolidation. Reconsolidation is what happens when a memory is recalled and then becomes malleable again. Consolidation is the original encoding. That these are different processes, and that CBD may affect them differently, is the kind of detail that gets flattened into "CBD improves memory".

A 2024 paper in Acta Neuropsychiatrica is the one that comes closest to the plasticity question in the title. It reported that cannabidiol improved non-motor symptoms, attenuated neuroinflammation, and favoured hippocampal newborn neuron formation. That last part is the headline finding for anyone who has been reading about neurogenesis, and it is also the part that needs the most context, which is that it comes from a neurological disease population rather than healthy volunteers.

A 2026 paper in Psychiatry Research: Neuroimaging used imaging to look at the relationship between hippocampal glutamate and learning after a single dose of CBD, which is a rare example of this research being done in humans with brain measures rather than just behavioural tests.

The human research, and why it is thinner

Here is the part that most public writing skips, and it is the part that determines how much any of this should change your behaviour.

*The 2025 mini-review in Front Psychiatry*** on CBD and cognitive function in older adults is the most human-focused piece of this body of work, and it is worth reading precisely because it is a review of a mixed and limited evidence base rather than a parade of findings. Cognitive decline in older adults is a genuinely important question, and the honest answer is that the human evidence is not yet strong enough to draw firm conclusions.

*The 2024 study in Military Medical Research*** looked at Epidiolex, the prescription CBD, in Gulf War Illness, and reported alleviation of cognitive and mood dysfunction. This is one of the more interesting human data points, but it is a small, specific population with a specific prescription product, and it does not generalise to over-the-counter CBD in healthy people.

*The 2023 paper in Experimental and Clinical Psychopharmacology*** reviewed the use of CBD for cognitive impairment across psychiatric and neurological illness, which is the appropriate framing because cognitive impairment in those conditions is a clinical problem with clinical endpoints.

*The 2026 systematic review in Molecular Psychiatry*** looked at CBD's effects on anxiety-like and depressive-like behaviours alongside cognition, which is useful for establishing that effects on cognition in animal models are usually secondary to mood effects rather than direct cognitive enhancement.

And the 2026 paper in Journal of Neuroendocrinology, comparing CBD with hormonal therapy for oestrogen-decline-induced memory impairment, is a good example of the preclinical framing. Rodent models of menopause, with rodent memory assays, and a comparison against an existing therapy.

The honest verdict

Let me lay out what I think the evidence supports, and what it does not.

What it supports. Cannabinoids do modulate synaptic function, because the endocannabinoid system is a core part of synaptic regulation. CBD produces measurable changes in plasticity markers in animal models, particularly in the hippocampus. The effect is not trivial in those models. There is genuine mechanistic plausibility and genuine animal data.

What it does not support. That CBD improves cognition in healthy people. That it "rewires" or "regenerates" a brain. That the benefits seen in seizure models, depression models, or animal cognitive assays translate to a measurable cognitive improvement in a healthy 30-year-old who takes a dropper of CBD and expects to think more clearly.

The most likely real-world effect is a negative one. Most of the animal research showing cognitive improvement is in models of impairment. In healthy subjects, the picture is considerably less rosy, and some of it points the other way. The 2024 paper on driving in older adults, while not about CBD, is a useful reminder that cannabinoids and cognition have a complicated relationship, and that subjective confidence is not a reliable guide to performance.

Mouse brain is not human brain. Hippocampal structure differs, the ratio of neuron types differs, and the behavioural tests used in rodents do not map cleanly onto human cognition. A rodent that navigates a maze better is not a human who remembers more.

Dose and formulation matter enormously. A large share of the positive animal work uses formulations designed to get CBD into the brain at concentrations that oral products do not produce. When you read a headline about CBD and memory, the relevant question is what the researchers actually administered.

What this means in practice

If you are healthy and want to think better, this is not a reason to start. The evidence for cognitive enhancement in healthy people is weak, and the honest reading of the animal literature is that it mostly describes recovery from impairment rather than improvement beyond baseline.

If you are concerned about cognitive decline, the research is worth reading but the field is young. The 2025 mini-review in Front Psychiatry is the best single starting point, and it is more useful for understanding what is still unknown than for making a decision.

If you are already taking a prescription cannabinoid product, this literature is relevant to you. The Gulf War Illness work used Epidiolex, and if you are on a prescription cannabinoid the monitoring and the evidence base are different from the over-the-counter world.

If you take CBD and drive, work with a high load, or do anything safety-critical, be careful. This is not about plasticity research, it is about the well-documented observation that cannabinoids impair attention and reaction time, and the irony that the same brain changes people find appealing are the ones that make a task harder.

The most useful thing this research gives you is a way to read the marketing. When a product claims to "support brain plasticity" or "regenerate neural pathways", the questions that cut through the noise are these. Was the study in humans or animals? Was the subject impaired or healthy? What was the dose, and was it a form you could actually buy? Was the outcome a biomarker or a task someone did?

Bottom Line

The plasticity research is real, it is progressing quickly, and it is more interesting than most of what gets written about it. Cannabinoids do interact with a system that regulates synaptic function, and they do change plasticity markers in animal models, particularly in the hippocampus.

But the gap between a mechanism that is plausible and a benefit you can buy is wide, and the research does not close it. Almost all of the strongest positive data comes from models of brain injury, disease or impairment, in animals, often using formulations you cannot purchase. The human evidence is real but limited, and the one decent human review of CBD and cognition in older adults concludes that firm conclusions are premature.

So the honest summary is this. The science is worth following, and it should make you more thoughtful rather than more credulous about cannabis products. If something claims to rebuild your brain, ask which of the four kinds of plasticity it means, and then ask who was studied, in what state, with what dose.

If you want the receptor and endocannabinoid system background that this whole area sits on, our what is CBD guide covers it. The CBD for focus category is where products in this space tend to be marketed, and reading it alongside this article is a useful exercise in evaluating the claims. For the practical side of how long effects last and when to take them, how long does CBD take to work is the more useful reference.

---

This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before using CBD, especially if you take other medications, drive, operate machinery, or have underlying health conditions.